Continuous Infusion Homoharringtonine (NSC 141633) in Refractory Acute Nonlymphocytic Leukemia

Ja, Stewart; Pa, Cassileth; Jm, Bennett; Mj, O'Connell

doi:10.1097/00000421-198812000-00006

Cited by 13 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[34][35][36][37] However, significant activity was reported in phase 1/2 clinical trials in patients with AML in which HHT was administered as a continuous infusion. [38][39][40][41][42] In a compound analysis of 3 phase 1/2 trials in which 117 patients with refractory AML received HHT at doses from 5 mg/m 2 to 7 mg/m 2 daily by continuous infusion, 14 of 91 assessable patients (15%) attained a complete response (CR), and 1 patient achieved a partial response (PR). 38,39,43 In 1 of those trials, 38 the activity and safety of 3 different schedules of HHT was explored: 5 mg/m 2 for 7 days, 7 mg/m 2 for 7 days, and 5 mg/m 2 for 9 days.…”

Section: Phase 2 Studies Of Intravenous Hht In CMLmentioning

confidence: 99%

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009

Quintás‐Cardama

Kantarjian²,

Cortés

2009

Cancer

View full text Add to dashboard Cite

Homoharringtonine (HHT) is a natural alkaloid that is obtained from various Cephalotaxus species. The mechanism of action by which HHT exerts its antitumor activity is through inhibition of protein synthesis and promotion of apoptosis. In the 1990s, HHT proved to be significantly active as salvage therapy for patients with chronic myeloid leukemia (CML) after failure on interferon-a therapy. However, the remarkable success of imatinib mesylate in the treatment of CML relegated HHT to oblivion. The development of omacetaxine mepesuccinate, a subcutaneously bioavailable semisynthetic form of HHT, and its activity in imatinib-resistant CML has established this agent for the second time as a valuable option in the management of this disease. Preliminary results appear to support the use of this agent for patients who have imatinibresistant CML, including those who carry the tyrosine kinase inhibitor-insensitive mutation that exchanges the amino acids threonine and isoleucine at position 315 (the T315I mutation). In this article, the authors discuss the current data on omacetaxine and the prospects of this agent to be integrated into the state-ofthe-art treatment algorithms for CML.

show abstract

Section: Phase 2 Studies Of Intravenous Hht In CMLmentioning

confidence: 99%

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009

Quintás‐Cardama

Kantarjian²,

Cortés

2009

Cancer

View full text Add to dashboard Cite

show abstract

“…78 Kantarjian et al 79 investigated HHT in a lower dose, longer infusion schedule of 2.5-3 mg/m 2 by continuous infusion daily for 14 -21 days in patients with refractory-recurrent acute leukemia in an attempt to demonstrate efficacy without hypotensive events. Thirty-one patients received HHT as first (n ϭ 15) or second (n ϭ 16) salvage therapy.…”

Section: Stewart Et Al Did Not Obtain Any Crs In 20 Patientsmentioning

confidence: 99%

Homoharringtonine

Kantarjian

Talpaz

Santini

et al. 2001

Cancer

166

View full text Add to dashboard Cite

“…With the exception of homoharringtonine which has shown some minor efficacy in the treatment of acute myelogenous leukemia, these agents have shown little promise to date in the treatment of human malignancies (22)(23)(24)(28)(29)(30)(31). Prestudy characteristics of the patients on this study as analyzed according to the above discussed prognostic index fully predict the prognosis of the reported cohort.…”

Section: Discussionmentioning

confidence: 99%

“…Aside from the usually expected myelosuppression and gastrointestinal toxicity, cardiovascular toxicity manifested by hypotension and dysrhythmia was also seen. Initial phase iI trials have indicated activity in acute myelogenous leukemia [22][23][24].…”

Section: Introductionmentioning

confidence: 99%

A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer

et al. 1996

View full text Add to dashboard Cite

Forty-eight previously untreated, ambulatory patients with advanced or unresectable renal carcinoma were treated with either amonafide (17 patients), caracemide (17 patients), or homoharringtonine (14 patients). No objective responses were observed in any of the treatment cohorts. Amonafide and caracemide were well tolerated with no unexpected toxicities. One patient each died of pulmonary thromboembolism and sepsis with severe metabolic acidosis on the homoharringtonine arm. An additional 4 patients experienced grade 4 complications including myelosuppression, neurologic dysfunction, and respiratory failure. These severe and unexpected complications caused early termination of accrual to the homoharringtonine arm of the study. These agents have no activity in the treatment of advanced renal cell carcinoma.

show abstract

Continuous Infusion Homoharringtonine (NSC 141633) in Refractory Acute Nonlymphocytic Leukemia

Cited by 13 publications

References 0 publications

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009

Homoharringtonine

A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer

Contact Info

Product

Resources

About